Sitagliptin

• Target :

  DPP-4|||Proteasome|||Autophagy

• Related Pathways :

  Autophagy|||Proteases/Proteasome|||Ubiquitination

• Purity :

  0.9983

• Bioactivity :

  Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.

• Smiles :

  N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F

• Molecular Formula :

  C16H15F6N5O

• Molecular Weight :

  407.31

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  486460-32-6